GDC 0425

Drug Profile

GDC 0425

Alternative Names: GDC-0425; RG-7602

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 01 May 2014 Genentech completes a phase I trial in Lymphoma and Solid tumours (late-stage disease) in USA and France (NCT01359696)
  • 30 Jan 2014 Discontinued - Phase-I for Lymphoma and Solid tumours (late-stage disease) in USA and France (PO)
  • 17 Oct 2013 GDC 0425 is still in phase I trials for Solid tumours and Lymphoma (late-stage disease) in USA and France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top